Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study

Tristan Ferry; Anne Conrad; Eric Senneville; Sandrine Roux; Céline Dupieux-Chabert; Aurélien Dinh; Sébastien Lustig; Sylvain Goutelle; Thomas Briot; Truong-Thanh Pham; Florent Valour

doi:10.1093/ofid/ofab351

Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study

Open Forum Infect Dis. 2021 Jul 2;8(7):ofab351. doi: 10.1093/ofid/ofab351. eCollection 2021 Jul.

Authors

Tristan Ferry^{1

2

3}, Anne Conrad^{1

2

3}, Eric Senneville^{4

5

6}, Sandrine Roux^{1

2}, Céline Dupieux-Chabert^{1

2

3}, Aurélien Dinh^{7

8}, Sébastien Lustig^{2

9}, Sylvain Goutelle^{1

2

10}, Thomas Briot^{1

2}, Truong-Thanh Pham^{1

2

11}, Florent Valour^{1

2

3}

Affiliations

¹ Infectious Diseases Department, Croix-Rousse Hospital, Lyon, France.
² French Referral Centre for Complex Bone and Joint Infections, Centre de Référence des Infections Ostéo-Articulaires complexes Lyon, Lyon, France.
³ Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR 5308, ENS de Lyon, UCBL1, Lyon, France.
⁴ Infectious Diseases Department, Gustave Dron Hospital, Lille,France.
⁵ Faculty of Medicine Henri Warembourg, Lille University, Lille,France.
⁶ French Referral Centre for Complex Bone and Joint Infections, Centre de Référence des Infections Ostéo-Articulaires complexes Lille-Tourcoing, Lille,France.
⁷ Infectious Diseases Department, Ambroise Paré Hospital, Boulogne-Billancourt,France.
⁸ French Referral Centre for Complex Bone and Joint Infections, Centre de Référence des Infections Ostéo-Articulaires complexes Paris-Ambroise, Paré,France.
⁹ Orthopaedic Surgery Department, Croix-Rousse Hospital, Lyon, France.
¹⁰ Université Lyon, Université Lyon 1, UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France.
¹¹ Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Abstract

A prospective cohort study was conducted to evaluate long-term safety of tedizolid as suppressive antimicrobial treatment in patients with implant-associated bone and joint infection caused by multidrug-resistant gram-positive pathogens. Seventeen patients received tedizolid with a median duration of treatment of 6 months. No patients developed a serious adverse event.

Keywords: bone and joint infection; linezolid; periprosthetic joint infection; suppressive antimicrobial therapy; tedizolid.